Inoue balloon mitral valvuloplasty: Long-term clinical and echocardiographic follow-up of a predominantly unfavourable population

Abstract

Aims: To assess long-term outcome in a typical Western population of predominantly unfavourable patients undergoing Inoue balloon mitral valvuloplasty. Outcome amongst patients has only been undertaken in the medium term. Long-term echocardiographic data in particular are scarce. Methods: Inoue mitral valvuloplasty was attempted in 106 patients. There were six technical failures; the procedure was therefore completed in 100 patients, who underwent annual clinical and echocardiographic follow-up. Results: Patients were aged 63.5 ± 10.3 years. 82% were female. Unfavourable characteristics included age >65 (52%), NYHA class III or IV (87%), ≥ 1 significant co-morbidity (63%), atrial fibrillation (82%), previous surgical commissurotomy (25%) and echocardiographic score >8 (59%, mean 8.9 ± 2.1). Mitral valve area increased from 0.98 ± 0.23 to 1.54 ± 0.31 cm2. There were three major complications. Post-procedure, symptoms improved in 88% of patients. Haemodynamic success (mitral valve area increase >50%, final mitral valve area >l.5cm2, mitral regurgitation ≤grade 2) was achieved in 61% of cases. Mean follow-up was 4.3 ± 1.4 years. Survival was 97%, 88% and 82% at 1, 3 and 6 years. Event-free survival (freedom from death, mitral valve replacement or repeat valvuloplasty) was 96%, 82% and 56% at 1, 3 and 6 years. Freedom from restenosis (loss of >50% gain in mitral valve area, mitral valve area <1.5cm2) was 98%, 92% and 75% at 1, 3 and 6 years. Pre-procedural predictors of event-free survival were male sex, absence of comorbidities, lower echocardiographic score and smaller left atrial diameter. Conclusions: In a Western population with predominantly unfavourable characteristics for mitral valvuloplasty, long-term outcome post-procedure is reasonable. A moderate increase in nutral valve area can be achieved at low procedural risk, and the subsequent rate of restenosis is low. Nonetheless, 6 years after the procedure, half of the patients will have required further intervention or died. For fitter patients willing to accept significant operative risk, mitral valve replacement remains a valuable alternative. (C) 2000 The European Society of Cardiology.